Earthquake :: Discovery sheds new light on cause of earthquakes
Research at the University of Liverpool into a large fault zone in the Atacama Desert in northern Chile has produced new insight into how fluid pressure can cause earthquakes.
University
Water :: New observations on properties of water
Recent experiments on the properties of water by Ph.D. Anatoli Bogdan, University of Helsinki,reveal information relevant for cloud physics and even cryopreservation science.
Lung Cancer :: Avastin drug chokes off tumor blood vessels offers new hope to lung cancer patients
Patients suffering from the most common type of lung cancer experienced a 20-percent improvement in overall survival in a national clinical trial of a drug that chokes off the blood vessels nourishing tumors, a multicenter study has found.
Breast Cancer :: Restoring Tamoxifen Sensitivity in Resistant Breast Cancer
The widely used breast cancer drug tamoxifen (Nolvadex?), which can become less effective over time, might retain its full strength indefinitely if used along with a second drug, according to new research in mice conducted by investigators from the National Cancer Institute (NCI), part of the National Institutes of Health, and their partners. The results appear in the December 11, 2006, issue of Cancer Cell.
Schizophrenia :: ABILIFY, Aripiprazole for Adults With Agitation Associated With Schizophrenia or Bipolar Mania
Bristol-Myers Squibb Company (NYSE: BMY) and Otsuka Pharmaceutical Co., Ltd. today announced the launch of ABILIFY? (aripiprazole) Injection, an injectable form of ABILIFY, for intramuscular use. ABILIFY Injection provides rapid control of agitation in adults with schizophrenia or bipolar mania at primary endpoint (2 hours).
Leukemia :: SPRYCEL, dasatinib 100 MG Once A Day more effective in leukemia
Today, Bristol-Myers Squibb Company (NYSE: BMY) announced results from a randomized Phase III study showing that patients receiving SPRYCEL 100 mg once a day achieved similar cytogenetic responses at six months with considerably fewer hematologic and non-hematologic adverse events than patients receiving three other dosing schedules of SPRYCEL.
Surgery :: Dabigatran etexilate, a new oral anticoagulant is effective and safe in preventing thromboembolic disease
In future, the prevention of venous thromboembolism (VTE) in thousands of patients after knee-replacement surgery may become much easier with a new agent in capsule form, called dabigatran etexilate.
Colorectal Cancer :: Xeloda meets primary endpoint in multinational Phase III advanced colorectal cancer study
Roche announced today that a large, international Phase III study (NO16967) of 627 previously treated patients with advanced colorectal cancer met its primary endpoint of progression-free survival.
Nystagmus :: Leicester breakthrough in eye disease
Researchers at the University of Leicester have identified for the first time a gene which causes a distressing eye condition. Their discovery, as reported in the journal Nature Genetics, is expected to lead to better treatments for the condition.
Prostate Cancer :: older men with early prostate cancer treated lived longer
SEER-Medicare analysis finds older men with early prostate cancer who were treated lived longer than those who were not treated. Study published in Dec. 13th issue of JAMA.